Qiagen N.V. logo QGEN - Qiagen N.V.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 13
HOLD 17
SELL 0
STRONG
SELL 0
| PRICE TARGET: $44.12 DETAILS
HIGH: $59.00
LOW: $36.00
MEDIAN: $43.00
CONSENSUS: $44.12
UPSIDE: 6.98%

Stock News

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States. More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000 potential cases, as health authorities investigate multiple outbreaks involving Cyclospora cayetanensis,.

Jul 15, 2026 12:05 PM • businesswire.com
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click her.

Jul 15, 2026 04:48 AM • businesswire.com
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe. The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour. It comp.

Jul 14, 2026 12:05 PM • businesswire.com
Qiagen: New Launches Signal A Turnaround

Qiagen: New Launches Signal A Turnaround

Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation.

Jul 12, 2026 01:08 AM • seekingalpha.com
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications. As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabi.

Jun 14, 2026 09:30 PM • businesswire.com
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater s.

May 28, 2026 12:05 PM • businesswire.com
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.

QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N. V. ("Qiagen" or the "Company") (NYSE: QGEN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

May 21, 2026 04:00 PM • globenewswire.com (Hide legal announcements)

Price Targets